Latest News - Gilead Sciences
Top Corporates Hub
Gilead Sciences
3 Stocks Estimated To Be Trading At Discounts Of Up To 44.1%
26.05.2026 11:38
The United States market has shown robust performance, climbing 1.2% in the last week and rising 29% over the past year, with earnings projected to grow by 17% annually in the coming years. In such a thriving environment, identifying stocks that are trading below their intrinsic value can present attractive opportunities for investors seeking potential long-term gains.
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
24.05.2026 13:03
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital Markets senior biotech analyst Brian Abrahams. Berger said Gilead is focused on advancing Trodel
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains
23.05.2026 07:18
If you are wondering whether Gilead Sciences at US$134.36 is still offering value, the starting point is to understand what the current market price is implying about the business. The stock has returned 3.7% over the last 7 days, 1.1% over the last 30 days, 10.5% year to date, 28.5% over 1 year, 92.9% over 3 years and 144.9% over 5 years, which gives useful context for how expectations and perceived risk have shifted over time. Recent coverage has focused on Gilead Sciences as a large...
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
22.05.2026 11:47
FOSTER CITY, Calif., May 22, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) as a monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metasta
Gilead Sciences completes Tubulis acquisition for $5bn
22.05.2026 11:19
Gilead acquired all outstanding equity of Tubulis for $3.15bn upfront, plus up to $1.85bn in milestone payments.
Gilead Sciences Says CHMP Of EMA Adopts Positive Opinion, Recommending Marketing Authorization Of Trodelvy As Monotherapy For Treatment Of Adult Patients With Triple-Negative Breast Cancer; EU Decision Expected Later 2026
22.05.2026 07:56
– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients–– Positive– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
21.05.2026 13:30
FOSTER CITY, Calif., May 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs).
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
21.05.2026 07:30
FOSTER CITY, Calif., May 21, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a renewed five-year collaboration with the World Health Organization (WHO), committing funding, strategic support and product donations to accelerate progress toward eliminating visceral leishmaniasis (VL), also known as kala-azar. VL, the second deadliest parasitic disease after malaria, is a sandfly-borne illness that attacks internal organs and can be fatal if untreated.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
20.05.2026 13:00
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Morgan Stanley Reassesses Gilead Sciences (GILD) Outlook Following Quarterly Report
20.05.2026 11:49
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 10 Best Long Term Low Risk Stocks to Buy According to Hedge Funds. On May 10, Morgan Stanley lowered its price recommendation on Gilead Sciences, Inc. (NASDAQ:GILD) to $168 from $175. It reiterated an Overweight rating on the shares. The firm updated its model for the company […]
Maxim Group Upgrades Gilead Sciences to Buy, Announces $165 Price Target
20.05.2026 08:49
Maxim Group analyst Michael Okunewitch upgrades Gilead Sciences (NASDAQ:GILD) from Hold to Buy and announces $165 price target.
Gilead Sciences (NASDAQ:GILD) Screens as a Top Dividend Stock with Strong Profitability and Health
19.05.2026 09:00
Gilead Sciences offers a 2.48% dividend yield, strong financial health, and an 8/10 profitability rating, making it a top pick for reliable dividend income.
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
19.05.2026 08:17
Compugen (CGEN) is maintained at a Buy rating, driven by advancing clinical programs and upcoming catalysts in oncology.
3 Market-Beating Stocks to Research Further
19.05.2026 05:32
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
17.05.2026 13:03
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
16.05.2026 14:10
Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of directors Alexis Borisy and Kanishka Pothula, with Sung Lee appointed Lead Independent Director. Alongside a cash balance of about US$380 million expected to fund operations into 2028, the company is refocusing its oncology pipeline by prioritizing MTAP-deleted selective PRMT5 programs and...
Gilead Prices $3 Billion of Senior Unsecured Notes
15.05.2026 01:21
FOSTER CITY, Calif., May 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.600% senior notes maturing i
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
14.05.2026 11:05
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026
13.05.2026 12:30
FOSTER CITY, Calif., May 13, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis.
Gilead's Transition Into A Long-Duration Biotech Platform
13.05.2026 09:15
Gilead (GILD) stock analysis: HIV/PrEP and oncology growth fuel a diversified platform and profit strength, supporting Buy and 10â15% upsideâread now.